$2.21 Billion is the total value of NEA Management Company, LLC's 36 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | TESARO INC | $565,634,000 | +54.3% | 9,854,255 | 0.0% | 25.58% | +43.9% | |
| GRPN | GROUPON INC | $318,487,000 | -12.7% | 44,172,953 | 0.0% | 14.40% | -18.6% | |
| CLVS | CLOVIS ONCOLOGY INC | $169,228,000 | +32.6% | 2,279,781 | 0.0% | 7.65% | +23.6% | |
| SUPN | SUPERNUS PHARMACEUTICALS INC | $128,759,000 | +45.7% | 10,650,000 | 0.0% | 5.82% | +35.9% | |
| HPTX | HYPERION THERAPEUTICS INC | $109,436,000 | +91.3% | 2,384,221 | 0.0% | 4.95% | +78.3% | |
| EPZM | EPIZYME INC | $96,712,000 | -0.5% | 5,149,740 | 0.0% | 4.37% | -7.2% | |
| OPWR | OPOWER INC | $91,143,000 | -28.8% | 8,997,290 | 0.0% | 4.12% | -33.6% | |
| CVT | CVENT INC | $84,029,000 | +0.7% | 2,996,738 | 0.0% | 3.80% | -6.1% | |
| ARDX | ARDELYX INC | $73,581,000 | -30.7% | 5,621,199 | 0.0% | 3.33% | -35.4% | |
| GLYC | GLYCOMIMETICS INC | $71,345,000 | +15.6% | 8,575,135 | 0.0% | 3.23% | +7.7% | |
| NVRO | NEVRO CORP | $65,659,000 | +23.9% | 1,369,899 | 0.0% | 2.97% | +15.6% | |
| DERM | New | DERMIRA INC | $53,827,000 | – | 3,506,649 | +100.0% | 2.43% | – |
| TRIV | TRIVASCULAR TECHNOLOGIES INC | $41,385,000 | -16.5% | 3,945,191 | 0.0% | 1.87% | -22.2% | |
| TRVN | TREVENA INC | $31,372,000 | +9.0% | 4,811,691 | 0.0% | 1.42% | +1.7% | |
| VTAE | VITAE PHARMACEUTICALS INC | $30,601,000 | -29.6% | 2,613,199 | 0.0% | 1.38% | -34.3% | |
| OREX | OREXIGEN THERAPEUTICS INC | $29,041,000 | +29.2% | 3,709,000 | 0.0% | 1.31% | +20.5% | |
| TCON | New | TRACON PHARMACEUTICALS INC | $26,531,000 | – | 1,889,652 | +100.0% | 1.20% | – |
| CRCM | CARE COM INC | $24,718,000 | -8.5% | 3,260,989 | 0.0% | 1.12% | -14.6% | |
| LOXO | LOXO ONCOLOGY INC | $22,313,000 | +6.0% | 1,792,207 | 0.0% | 1.01% | -1.2% | |
| ZSAN | New | ZOSANO PHARMA CORP | $21,823,000 | – | 2,158,543 | +100.0% | 0.99% | – |
| HIVE | AEROHIVE NETWORKS INC | $21,682,000 | -7.1% | 4,861,455 | 0.0% | 0.98% | -13.4% | |
| WIFI | Sell | BOINGO WIRELESS INC | $18,822,000 | -29.1% | 2,496,312 | -27.8% | 0.85% | -33.9% |
| LXRX | LEXICON PHARMACEUTICALS INC | $15,675,000 | +3.3% | 16,676,000 | 0.0% | 0.71% | -3.7% | |
| TRGT | TARGACEPT INC | $13,563,000 | +12.9% | 4,566,666 | 0.0% | 0.61% | +5.3% | |
| MM | MILLENNIAL MEDIA INC | $11,926,000 | -9.4% | 8,224,752 | 0.0% | 0.54% | -15.5% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $11,578,000 | +57.3% | 3,243,150 | 0.0% | 0.52% | +46.8% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $11,415,000 | -3.9% | 4,659,333 | 0.0% | 0.52% | -10.4% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $11,104,000 | +19.8% | 2,546,843 | 0.0% | 0.50% | +11.6% | |
| ROKA | ROKA BIOSCIENCE INC | $10,305,000 | -27.4% | 3,220,433 | 0.0% | 0.47% | -32.4% | |
| ZHNE | ZHONE TECHNOLOGIES INC | $6,216,000 | -26.6% | 4,781,290 | 0.0% | 0.28% | -31.5% | |
| EXEL | EXELIXIS INC | $5,672,000 | +78.5% | 2,207,000 | 0.0% | 0.26% | +66.2% | |
| ARQL | ARQULE INC | $5,646,000 | +83.6% | 2,520,316 | 0.0% | 0.26% | +71.1% | |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $5,436,000 | -18.9% | 173,892 | -0.0% | 0.25% | -24.3% |
| ECOM | CHANNELADVISOR CORP | $5,394,000 | -55.1% | 556,692 | 0.0% | 0.24% | -58.1% | |
| AGRX | Buy | AGILE THERAPEUTICS INC | $1,237,000 | +54.2% | 133,488 | +2.2% | 0.06% | +43.6% |
| NURO | NEUROMETRIX INC | $96,000 | -14.3% | 57,273 | 0.0% | 0.00% | -20.0% | |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -5,653,029 | -100.0% | -2.28% | – |
| RNA | Exit | PROSENSA HLDG NV | $0 | – | -6,480,171 | -100.0% | -5.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.